Steve Harr, Sana Biotechnology CEO
June 2, 2022 08:10 AM EDTUpdated June 3, 05:16 PM
Manufacturing

Sana banks on $100M sav­ings as it shifts man­u­fac­tur­ing plans to Wash­ing­ton state

Tyler Patchen

News Reporter

The ex­ecs at Sana are drop­ping plans to build their new cell and gene ther­a­py man­u­fac­tur­ing fa­cil­i­ty in Cal­i­for­nia, in­stead turn­ing close to their home …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times